As patients with COVID-19 pneumonia admitted to intensive care unit (ICU) have high rates
of thrombosis, high doses of thromboprophylaxis have been proposed. The associated …

A prothrombotic state is reported with severe COVID-19 infection, which can manifest in
venous and arterial thrombotic events. Coagulopathy is reflective of more severe disease …

Introduction COVID-19 may predispose to both venous and arterial thromboembolism due to
excessive inflammation, hypoxia, immobilisation and diffuse intravascular coagulation …

Background Studies report hypercoagulability in coronavirus disease 2019 (COVID‐19),
leading many institutions to escalate anticoagulation intensity for thrombosis prophylaxis …

Background A significant proportion of patients with coronavirus disease 19 (COVID-19)
suffer from excessive coagulation activation and coagulopathy which is associated with an …

Background The coronavirus disease 2019 (COVID-19) causes extensive coagulopathy and
a potential benefit of anticoagulation therapy has been documented for prevention of …

Introduction Some local protocols suggest using intermediate or therapeutic doses of
anticoagulants for thromboprophylaxis in hospitalized patients with coronavirus disease …

Patients with coronavirus disease 2019 (COVID-19) have elevated D-dimer levels. Early
reports describe high venous thromboembolism (VTE) and disseminated intravascular …

Background There is no current standardized approach to anticoagulation in patients with
Coronavirus Disease 2019 (COVID-19) while potential bleeding risks remain. Our study …

Coronavirus disease 2019 (COVID-19) is a new, emerging medical challenge worldwide,
with those affected showing a variety of clinical presentations, ranging from asymptomatic or …